{"id":14937,"date":"2012-06-06T02:30:00","date_gmt":"2012-06-06T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/scaccabarozzi-altri-risparmi-forse-da-brevetti-noi-gia-super-controllati\/"},"modified":"2012-06-06T02:30:00","modified_gmt":"2012-06-06T00:30:00","slug":"scaccabarozzi-altri-risparmi-forse-da-brevetti-noi-gia-super-controllati","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/scaccabarozzi-altri-risparmi-forse-da-brevetti-noi-gia-super-controllati\/","title":{"rendered":"Scaccabarozzi, other savings? Perhaps from patents, we already super-controlled"},"content":{"rendered":"

The possible savings margins in the pharmaceutical sector "of which the Minister of Health speaks", in the interview with Corriere della Sera, "could be those deriving from the expiry of patents on medicines. But the problem is that if invest these resources in innovation, the problems remain".<\/p>\n

<\/font><\/font><\/span><\/p>\n

The president of Farmindustria, Massimo Scaccabarozzi, told Pharmakronos Salute, commenting on Balduzzi's statements to the newspaper in via Solferino. The minister highlighted that "pharmaceuticals have already been subject to revision since last July, regardless of the extraordinary expenditure revision. The savings margins are not infinite, but they exist".<\/p>\n

<\/font><\/font><\/span><\/p>\n

According to Scaccabarozzi, "although it is not clear what the minister is referring to, the pharmaceutical sector is truly a sector that has been subjected to extremely strict regimes of control for some time. The July 2011 maneuver, like the Abruzzo decree, set a savings target with random numbers.In addition, pharmaceutical spending in Italy is the lowest in Europe. <\/p>\n

<\/font><\/font><\/span><\/p>\n

Minister Passera also stressed the importance of growth and maintaining jobs. In this sense, we are an important sector and, in the event of further cuts, there would be a concrete risk in this sense".<\/p>\n

<\/font><\/font><\/span><\/p>\n

June 6, 2012 \u2013 Barbara Di Chiara \u2013 PharmaKronos<\/p>\n

<\/span><\/i><\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

I margini di risparmio possibili nel settore della farmaceutica "di cui parla il ministro della Salute", nell’intervista al Corriere della Sera, "potrebbero essere quelli che derivano dalla scadenza dei brevetti sui medicinali. Ma il problema è che se non si re-investono queste risorse in innovazione, i problemi rimangono". Lo dice a Pharmakronos Salute il presidente …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14937","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14937"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14937\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}